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ABSTRACT 
Cardiovascular disease (CVD) is the leading cause of death in patients with end-stage renal disease (ESRD) 
treated by dialysis. Pulse pressure (PP) as an independent prognostic factor of cardiovascular risk might 
be clinically implicated in predicting the short-term deaths due to cardiovascular diseases in ESRD 
patients. This study aimed to investigate the dose-response association between pulse pressure (PP) and 
risk of cardiovascular mortality in patients initialising peritoneal dialysis (PD).  All patients registered with 
the Henan Peritoneal Dialysis Registry (HPDR) between 2007 and 2014 were incorporated in the 
current cohort study. PP was assessed by the date of initialisation of PD and cardiovascular mortality 
in 2 years after the initialisation of PD was defined as the outcome. All accessible clinical 
measurements were screened as covariables.  Further dose–response relationships between PP and 
risks were explored using spline models. There was a non-linear relationship between PP and the risk of 
2-year death for a cardiovascular diseases (P < 0.001 for linearity test). The PP associated with the lowest 
risk of cardiovascular mortality was 61 (95% CI 56–64) mmHg.  In ESRD patients initialising PD, PP is a good 
prognostic factor of risk of short-term cardiovascular mortality. The risk is lowest with a PP of 56–64 
mmHg. 
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INTRODUCTION 
With the increase prevalence of chronic kidney disease (CKD), the number of patients with end-stage 
renal disease (ESRD) is increasing rapidly and is becoming one of the major life-threatening diseases 
worldwide 1-3. Cardiovascular disease is the leading cause of death in patients with ESRD treated by 
dialysis 4. It has been estimated that 40%–60% of deaths in peritoneal dialysis (PD) patients are due to 
cardiovascular events 2, 5, 6. 
Observational study has reported a non-linear association between blood pressure measures 
(systolic and diastolic blood pressure) and cardiovascular mortality among incident PD patients, with 
high blood pressure (particularly > 145/92 mmHg) being associated with a higher risk of 
cardiovascular mortality 7.  
Vascular stiffness has been revealed to increase myocardial afterload and oxygen demand, to lead to 
left ventricular hypertrophy and to limit coronary filling during diastole 8. The pulsatile component of 
blood pressure (pulse pressure (PP)) is a prognostic factor of large artery stiffness and a reflection of 
the atherosclerotic burden, which itself is an independent predictor of cardiovascular risk 9, 10. An 
elevated pulse pressure is associated with a higher cardiovascular mortality 11 
Previous cohort study revealed that PP was associated with 1-year all-cause mortality among patients 
underwent hemodialysis, with high PP (>60-69 mmHg) be associated with an increased risk of 
cardiovascular mortality 12. In another cohort, a significant association was found between 30-month 
all-cause mortality and PP independent of systolic and diastolic blood pressures, with 1 mmHg 
increase of PP associated with 20% higher risk of all-cause mortality 13. However few studies have 
addressed the association between PP and cardiovascular mortality among patients initialising PD in 
prospective cohorts. In particular the dose-response association between PP and cardiovascular 
mortality among incident PD patients was not very clear. The present study aimed to examine this 
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relationship and investigates whether a threshold exists for PP in predicting the risk of 2-year 
cardiovascular mortality among those initialising PD. 
METHODS 
Data source and study population 
 For this study, we used data from the Henan Peritoneal Dialysis Registry (HPDR) to develop and 
validate the risk score. Henan is a province in the Central of China with the population over 100 
million.  Briefly, the HPDR is operated under the auspices of the Department of Nephrology, the First 
Affiliated Hospital of Zhengzhou University and provides an independent audit and analysis of renal 
care in Henan, China. During the study period, information was prospectively collected electronically 
from all renal units across Henan. Data arriving at the HPDR are subjected to an algorithm which 
identifies suspicious values, which are then further verified and corrected where necessary by 
contacting the renal unit. This study was designed as a cohort study, which included all adults aged 
more than 18 years who commenced PD between 2007-2014 and who had at least two years’ follow-
up. Patients who died, underwent transplant or whose kidney function recovered within 90 days 
after initialisation of dialysis were excluded (n=16) to avoid a reverse causality association between 
predictors and outcome. This reflects the standard approach to investigating “real” ESRD patients 
among all those receiving PD care.  We randomly allocated two thirds of patients to the derivation 
dataset and the remaining one third to a validation dataset. Ethics approval was granted by the 
Clinical Research Ethics Committee of the First Affiliated Hospital of Zhengzhou University. Written 
informed consent was obtained from all participants before inclusion. 
Pulse pressure definition 
Pulse pressure was defined as systolic minus diastolic blood pressure. Both systolic and 
diastolic blood pressures were measured at the time when patients initializing PD treatment. 
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Defining outcome, covariables, and missing data 
 We defined our primary outcome as recorded death with clinically diagnosed cardiovascular disease 
14, 15. We also obtained data on other covariables (as listed in Table 1), which can be 
associated with pulse pressure to allow adjustment for confounding.  These data were 
measured at the time when patients started PD treatment. For co-variables used in the final 
model, our cohort had missing information on body mass index (13.5%), phosphorus (21.0%), albumin 
(20.0%), total protein (22.6%), total cholesterol (24.3%), low density lipoprotein (24.6%), fasting 
glucose (16.0%), sodium (8.0%), systolic blood pressure (4.8%), and diastolic blood pressure (4.8%). 
We used multiple imputation to replace missing values by using a chained equation approach based 
on all variables. We created 30 imputed datasets for missing variables that were then combined 
across all datasets by using Rubin’s rule to obtain final model estimates 16. 
 
Statistical methods 
We used Logistic regression model to calculate the incidence rate ratio for cardiovascular mortality 
according to pulse pressure levels. The dose-response associations between pulse pressure 
measurements and the risk of cardiovascular mortality was estimated using a linear model, a natural 
cubic spline model with three equally spaced knots determined from the level of pulse pressure 
measures, and a quadratic spline models. The natural cubic spline model was chosen as the best-fit 
model for the relationship curve because of its lowest Akaike information Criterion compared with 
those of the linear model or quadratic spline model. For sensitivity analysis, the natural cubic spline 
models for the overall dataset were repeated using other potential knots, chosen to lie within the 
range for minimum to maximum measure of pulse pressure. A linear test was used in the natural 
cubic spline model to test its linearity of the relationship. The break-point test was carried out to 
target the potential thresholds (Percentile 5 to Percentile 95 of pulse pressure measures) by 
6 
incorporating the piecewise term into the cubic spline model. The threshold with a significant break 
in the regression coefficients and achieving the minimum AIC was chosen as the final threshold. The 
95% CI of the threshold was obtained from 1000 bootstrap samples. 
All analyses were performed using STATA (STATA SE 15.0 StataCorp, College Station, TX, USA). All P 
values were calculated using two-tailed tests and a P value <0.05 was taken to indicate statistical 
significance. 
RESULTS 
Characteristics 
In our cohort, we analysed information on 3,054 patients with 437 cardiovascular deaths within 2 
years of initialisation of PD. Table-1 summarises the basic characteristics of the study population. 
3,054 patients with mean age 48.9 years initializing PD treatment were included in this study. The 
prevalence of pre-existing cardiovascular diseases and type 2 diabetes was 45.3% and 14.7%, 
respectively. Within 2 years since initialisation of PD, 14.3% deaths due to cardiovascular diseases 
were observed. 
Distribution of PP 
The distribution of PP was presented in Figure-1. Patients with cardiovascular deaths within 2 years 
of initialisation of PD were more likely to have higher levels of PP comparing with those without 
cardiovascular deaths, as the median with interquartile range was 70.8 (59.0 to 79.1) and 60.0 (50.1 
to 70.2) mmHg, respectively. 
Association between PP ad CVD mortality and potential threshold 
Dose-response relationship curves were derived from the natural cubic spline models within original 
dataset with adjustment of covariables in Figure-2, which was similar to dose-response relationship 
curves were derived from the natural cubic spline models within imputed datasets with adjustment 
of covariables in Supplemental Figure-1. There was a non-linear relationship between PP and risk of 
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cardiovascular mortality (linearity test: P < 0.0001). There was strong evidence that a threshold of PP 
estimated at 61 (95% confidence interval: 56-64) mmHg was associated with the lowest risk of 
cardiovascular mortality, as tested by linear threshold models. The increased cardiovascular mortality 
risks were observed among those with PP above the threshold (Table-2).  
DISCUSSION 
We have found that non-linear association between PP and risk of 2-year cardiovascular mortality 
among patients initialising PD. To our knowledge, this is the first study to examine such risks and we 
provide strong evidence of a threshold in the relationship between PP and risk of short-term 
cardiovascular deaths at a PP of 61 mmHg. 
PP as an independent prognostic factor of cardiovascular risk has been well established by previous 
observational and intervention studies, in which PP was associated with increased all-cause mortality 
from populations underwent dialysis. For example, in a French cohort, it was found PP, a surrogate 
measure of arterial stiffness, is a better predictor of all-cause mortality risk than either systolic or 
diastolic blood pressure, at least among hemodialysis patients aged > 50 years 17. The independent 
prognostic value of PP in predicting mortality among people having end-stage renal diseases or 
undergoing dialysis has also been shown previously 12, 13. 
The risks of elevated blood pressure have been repeatedly demonstrated by clinical observational 
studies. Many studies have described a gradual increase in the risk of mortality with increasing levels 
of PP, especially in patients treated by dialysis. In a US retrospective national cohort study, in 
patients undergoing maintenance hemodialysis, an incremental increase of 10 mmHg in post-dialysis 
PP was associated with a 12% increase in the hazard for all-cause death within 12 months 12. In another 
US cohort study, it was found that every 10 mm Hg decrease in pulse pressure during dialysis was 
associated 20% of decrease of 6-month all-cause hospitalisation or deaths among patients 
undergoing maintenance hemodialysis 18. In a French cohort, over median 6.5 years follow-up, 1.85 
8 
fold risk of cardiovascular death was observed by every 10 mmHg increase of PP among patients 
treated by hemodialysis 17. 
Although cardiovascular mortality/incidence has been found to have a U-shaped relationship with 
systolic/diastolic blood pressure in patients with end-stage renal diseases before in epidemiological 
studies 7, 19, its J-shaped relationship with PP has not previously been investigated, especially in terms 
of the continuous association rather than the categorization of PP. In the US hemodialysis cohort, a 
J-shape association between PP and 1-year all-cause mortality was identified and PP more than 61 
mmHg was found to be associated with significant higher risk of 1-year all-cause mortality 12. 
Consistent with previous studies, the present study showed a much higher risk of cardiovascular 
mortality in patients initializing PD whose pulse pressure was both above and below 61 mmHg. 
The lowest mortality from cardiovascular diseases (i.e. threshold ) has previously been identified at 
145/92 mmHg, based on its J-shape relationship with blood pressure in patients initialising PD 7.In 
particular, two American PD cohorts identified a PP threshold at 49-67 mmHg among patients with 
mean age at 50-60 years 19. This finding was similar to the results of the present observational study 
where the lowest risk of cardiovascular mortality was found to be a PP of 61 mmHg for end-stage 
renal disease patients starting PD treatment. 
In patients with end-stage renal diseases, increases in oxidative stress, carbonyl stress and advanced 
glycation end-products may combine to exaggerate the alterations in collagen and elastin structure 
and function, with a resultant loss of vascular elasticity that leads to vascular stiffness. PP is thought 
to act as a surrogate for this clinical situation 20, 21. PP also reflects the vascular stiffness that increases 
with advancing age and leads to coronary heart disease 22-24. As a result of the earlier vascular aging 
that occurs with renal failure, an abnormal PP in people initialising PD could explain the risks of 
cardiovascular mortality observed in the present study 22-24. 
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Although systolic blood pressure is a strong surrogate in predicting the risk of cardiovascular 
mortality 7, it might still be worth observing PP in the daily care of people initialising PD in view of its 
independence as a prognostic factor of coronary mortality. Indeed, the elevated PP observed in 
people with initialisation of PD and the associated elevation in cardiovascular mortality may imply 
that PP should be a target for therapeutic intervention in these people. In the study by 
Lertdumrongluk et al. 19, which included people treated by hemodialysis, a reduction in PP was 
associated with an improvement in outcomes. 
Clinically, it is not clear how PP can be reduced: current antihypertensive treatment often focuses on 
reduction of the extracellular volume or smooth muscle cell tone, thereby reducing systolic and 
diastolic blood pressure. When both pressures are reduced, PP might not change. Nevertheless, 
identifying a high or low PP could prompt a review of cardiovascular disease risk factors, or degree 
of heart failure, with intensification of therapy if appropriate. This could include a discussion with the 
people about lifestyle factors such as smoking, diet and physical activity. For example, intervention 
could be prompted at PPs of ≤ 50 and ≥ 70 mmHg to take account of biological variation and 
accuracy issues (and to use rounded numbers to facilitate implementation). The feasibility and 
impact of such an intervention merits further investigation. 
Our results might be influenced by confounding by unmeasured risk factors, for example, those due 
to under-recording of pre-existing comorbidities and their duration. The duration of reduced renal 
function would be a particularly important measure prone to under-estimation. Secondly, we lacked 
data on lifestyle factors, including smoking, drinking and physical activity. Thirdly, we did not adjust 
for PD patients’ socioeconomic status that would likely impact on PD patients’ 
treatment/management status and their general health status. Fourthly, some clinical prognostic 
factors that could influence for cardiovascular death outcome, like left ventricular ejection fraction, 
pulmonary arterial pressure, right ventricular systolic pressure or adequacy of dialysis, et al, were not 
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available in this study, which suggesting that future external replication studies with more 
comprehensive clinical measurements are warranted. Finally, the proportion of clinical measurement 
data that was missing was relatively high requiring multiple imputation, which suggesting that 
further replication in the external dataset are warranted. 
CONCLUSION 
In summary, there was a non-linear relationship between PP and risk of cardiovascular mortality in 
patients initialising PD. The PP threshold for the lowest cardiovascular mortality was found to be 61 
(95% confidence interval: 56-64) mmHg. PP might be a useful prognostic factor to consider risk in 
clinical practice. 
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FIGURE LEGENDS 
Figure-1. Distribution of pulse pressure among patients with and without cardiovascular mortality 
 
1, indicates having cardiovascular mortality; 0, indicates having no cardiovascular mortality 
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Figure-2. Dose-response association between pulse pressure and risk of cardiovascular mortality 
among patients initializing peritoneal dialysis: estimated from original dataset 
 
Characteristics included in Table-1 were adjusted. 
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Table-1. Baseline Characteristics of study populations. 
Binary variable are displayed as numbers (percentage) and continuous variables are displayed as median 
(interquartile). 
  Characteristics 
N 3054 
Cardiovascular Deaths, n (%) 437 (14.3) 
Male Gender, n (%) 1790 (58.6) 
Primary Glomerular Disease, n (%) 1446 (47.3) 
Age, years 48.9 (38.2 to 59.0) 
Haemoglobin, g/L 88.0 (74.5 to 102.0) 
Packed cell volume  19.0 (2.5 to 27.5) 
Reticulocyte, %  4.8 (13.1 to 60.5) 
Phosphorus, mg/dl 1.8 (1.4 to 2.2) 
Albumin, g/L 33.5 (29.7 to 37.9) 
Total iron binding capacity , μmol/L 44.9 (35.0 to 53.0) 
FeTIBC, mmol/L 24.9 (20.9 to 41.0) 
Creatinine, µmol/L 840.8 (633.0 to 1066.0) 
estimated Glomerular Filtration rate, mL/min/1.73 m2 4.8 (3.6 to 6.8) 
Total protein, g/L 57.6 (52.2 to 63.1) 
Prealbumin, mg/L 29.3 (196.0 to 363.0) 
Total Cholesterol, mmol/L 4.4 (3.6 to 5.2) 
Low density lipoprotein, mmol/L 2.6 (1.9 to 3.4) 
Fasting glucose, mmol/L 5.0 (4.3 to 6.0) 
Sodium, mEq/L 140.0 (136.8 to 142.4) 
C-reaction protein, mg/dl 2.5 (1.0 to 5.5) 
Body mass index, kg/m2 22.7 (20.6 to 24.9) 
Systolic blood pressure, mmHg 144.0 (135.0 to 158.8) 
Diastolic blood pressure, mmHg 86.5 (80.0 to 95.0) 
Cardiovascular diseases, n (%) 1384 (45.3) 
16 
Type 2 Diabetes, n (%) 449 (14.7) 
Taking antihypertensive treatment, n (%) 1257 (41.2) 
 
 
 
 
 
Table-2. Adjusted incidence rates ratios for cardiovascular mortality by 1 unit increase in pulse 
pressure in groups classified by pulse pressure (61 mmHg) among patients initializing peritoneal 
dialysis 
 
 ‡ Indicates age and gender were adjusted; * indicates characteristics included in Table-1 were adjusted. 
 
 Pulse pressure ≤ 61 mmHg P-value Pulse pressure > 61 mmHg P-value 
Adjusted incident rates ratio‡ 0.93 (0.91 to 0.95) 0.047 1.17 (1.12 to 1.19) <0.0001  
Adjusted incident rates ratio* 0.96 (0.92 to 1.00) 0.063  1.26 (1.24 to 1.33) <0.0001   
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Supplemental Figure-1. Dose-response association between pulse pressure and risk of cardiovascular 
mortality among patients initializing peritoneal dialysis: estimated from imputed datasets 
 
Characteristics included in Table-1 were adjusted. 
 
 
 
